Evaxion A/S

Good morning, and welcome to the Avexian Biotech second quarter 2022 earnings call. All participants will be in a listen-only mode. Should you need any assistance today, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note that this event is being recorded. I would now like to turn the conference over to Corey Davis. Please go ahead.

Thanks, Joe. Hello, everyone. Thanks for joining us this morning. Let me quickly remind everyone that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they're not guarantees. A future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's annual report on Form 20F, filed on March 31, 2022, and the company's current and future reports filed with or submitted to the Securities and Exchange Commission. At this time, I'm pleased to turn the call over to Lars Wigner, the company's president and CEO. Lars, take it away.

Thank you, Corey. Good morning, everyone. So, thank you for joining us for this Evaction Biotech Q2 earnings call.